Takeda Pharmaceutical Limited (TAK) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Takeda Pharmaceutical Li... (TAK)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

13.05

0.06 (0.46%)

At close: Jan 14, 2025, 3:59 PM

13.04

-0.08%

After-hours Jan 14, 2025, 07:00 PM EST

undefined% (undefined)

Bid	12.93
Market Cap	41.37B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.57
PE Ratio (ttm)	22.89
Forward PE	n/a
Analyst	Buy

Ask	14.14
Volume	1,552,155
Avg. Volume (20D)	1,712,426
Open	13.03
Previous Close	12.99
Day's Range	13.00 - 13.10
52-Week Range	12.58 - 15.08
Beta	undefined

About TAK

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Reves...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jan 5, 2010

Employees 49,281

Stock Exchange NYSE

Ticker Symbol TAK

Website https://www.takeda.com

Analyst Forecast

According to 1 analyst ratings, the average rating for TAK stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Takeda Pharmaceutical Limited is scheduled to release its earnings on Jan 30, 2025, before market opens.
Analysts project revenue of $7.61M, reflecting a -99.9% YoY shrinking and earnings per share of 0.64, making a 25.49% increase YoY.

Why Price Moved

5 months ago · Source

+3.76%

Takeda shares are trading higher after the Europea... Unlock content with Pro Subscription

7 months ago · Source

-3.8%

Takeda Pharmaceutical shares are trading lower after the company announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial.

News

2 weeks ago · businesswire.com

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin I...

1 month ago · seekingalpha.com

Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors

Takeda Pharmaceutical offers a high dividend yield, but its sustainability is questionable due to exchange rate risks and a payout ratio often exceeding 100%. Despite growth in segments like Livtencit...

1 month ago · benzinga.com

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

On Tuesday, Takeda Pharmaceutical Company Limited TAK entered into an exclusive licensing agreement with Keros Therapeutics, Inc. KROS to further develop, manufacture and commercialize elritercept wo...

1 month ago · businesswire.com

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to f...

1 month ago · businesswire.com

Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform

TOKYO & BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a s...

2 months ago · youtube.com

Hennessy Japan Fund's Masa Takeda on the top Japanese stocks investors should watch

Masa Takeda, portfolio manager at Hennessy Japan Fund, joins CNBC's 'Power Lunch' to discuss why he's bullish on Japan, what president-elect Trump's proposed tariffs could mean for Japanese companies,...

2 months ago · seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2025 Earnings Call October 31, 2024 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President an...

2 months ago · reuters.com

Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments

Japan's Takeda Pharmaceutical returned to profitability in the second quarter following large impairment losses a year earlier and is restructuring to cut costs.

2 months ago · businesswire.com

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in it...